Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas
M Elbert, F Neumann, M Kiefer, K Christofyllakis… - Scientific Reports, 2024 - nature.com
Primary vitreoretinal lymphoma (PVRL) is a rare subtype of DLBCL and can progress into
primary central nervous system lymphoma (PCNSL). To investigate the role of chronic …
primary central nervous system lymphoma (PCNSL). To investigate the role of chronic …
[HTML][HTML] The b-cell receptor autoantigen LRPAP1 can replace variable antibody regions to target mantle cell lymphoma cells
M Bewarder, M Kiefer, H Will, K Olesch, C Moelle… - …, 2021 - journals.lww.com
Mantle cell lymphoma (MCL) accounts for 5%–10% of all lymphomas. The disease's genetic
hallmark is the t (11; 14)(q13; q32) translocation. In younger patients, the first-line treatment …
hallmark is the t (11; 14)(q13; q32) translocation. In younger patients, the first-line treatment …
[HTML][HTML] Autoantibodies against SUMO1-DHX35 in long-COVID
L Thurner, N Fadle, E Regitz, KD Preuss… - Journal of Translational …, 2022 - Elsevier
Long COVID is a collection of symptoms as a late sequelae of SARS-CoV-2 infection. It often
includes mental symptoms such as cognitive symptoms, persisting loss of smell and taste, in …
includes mental symptoms such as cognitive symptoms, persisting loss of smell and taste, in …
[HTML][HTML] Primary diffuse large B-cell lymphoma of the central nervous system: molecular and biological features of neoplastic cells
F Bertoni, M Montesinos-Rongen - Annals of Lymphoma, 2022 - aol.amegroups.org
Central nervous system diffuse large B-cell lymphoma (CNS-DLBCL), formerly named
primary CNS lymphoma (PCNSL), is an extranodal aggressive lymphoma manifesting solely …
primary CNS lymphoma (PCNSL), is an extranodal aggressive lymphoma manifesting solely …
Ars2‐containing bispecific, Fab‐and IgG1‐format BAR‐bodies to target DLBCL cells
Despite recent advances in the therapy of diffuse large B‐cell lymphoma, not otherwise
specified (DLBCL), around 30% of patients develop refractory disease or relapse after first …
specified (DLBCL), around 30% of patients develop refractory disease or relapse after first …
[PDF][PDF] The role of novel mast cell-derived SAMD14 in prostate cancer progression and tumour immunity
KAHHUIL TENG - 2022 - scholar.archive.org
Prostate cancer is the second most commonly diagnosed male cancer worldwide, and the
fifth leading cause of cancer death in men. Prostate cancer arises from the epithelial lining of …
fifth leading cause of cancer death in men. Prostate cancer arises from the epithelial lining of …
Integrierung des B-Zell-Rezeptor-Antigens Neurabin-I in ein IgG1-Antikörper-Format zur Therapie des primären diffus großzelligen B-Zell-Lymphoms des ZNS
CL Moelle - 2021 - publikationen.sulb.uni-saarland.de
Diese Arbeit stellt ein IgG1-Therapieformat vor, das die malignen B-Lymphozyten des
primären diffus großzelligen B-Zell-Lymphoms des zentralen Nervensystems über den …
primären diffus großzelligen B-Zell-Lymphoms des zentralen Nervensystems über den …